Bausch & Lomb Sues Slayback to Block Lumify Eye Drop Copycat

Bausch Health’s Bausch & Lomb unit and closely held Eye Therapies said Slayback’s proposed generic version of Lumify eye drops infringes two patents.

• Bausch is seeking court order blocking copies until patents have expired and cash compensation if copies are made before then, according to complaint filed Friday in federal court in Trenton, New Jersey
• Eye Therapies owns the patents and licenses them exclusively to Bausch, complaint says
  • Patents expire in July 2030: FDA Orange Book
• Lumify had sales of $29 million in the second quarter, Bausch CEO Joseph Papa said Aug. 3 in an earnings call, ...